Patents by Inventor Lene JESSEN

Lene JESSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20210363213
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Glucagon-GLP-1-GIP triple agonist compounds
    Patent number: 11111285
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20190270789
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 5, 2019
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS
    Publication number: 20190135886
    Abstract: The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Application
    Filed: September 5, 2018
    Publication date: May 9, 2019
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Glucagon-GLP-1-GIP triple agonist compounds
    Patent number: 10131702
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 20, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • GIP-GLP-1 dual agonist compounds and methods
    Patent number: 10100097
    Abstract: The present invention relates to truncated GIP analogs which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: October 16, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20160257729
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 8, 2016
    Applicant: Zealand Pharma A/S
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torbenä ØSTERLUND, Kate HANSEN, Lene JESSEN
  • GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS
    Publication number: 20150299281
    Abstract: The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Application
    Filed: May 3, 2013
    Publication date: October 22, 2015
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN